CombiMatrix Corporation (CBMX)
-NasdaqCM 3.29 
0.03(1.02%) 12:27PM EDT - Nasdaq Real Time Price
| Prev Close: | 3.32 |
|---|
| Open: | 3.32 |
|---|
| Bid: | 3.26 x 300 |
|---|
| Ask: | 3.29 x 200 |
|---|
| 1y Target Est: | 15.00 |
|---|
| Beta: | 0.49 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 3.22 - 3.44 |
|---|
| 52wk Range: | 1.40 - 14.14 |
|---|
| Volume: | 116,858 |
|---|
| Avg Vol (3m): | 789,425 |
|---|
| Market Cap: | 9.57M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -6.16 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- COMBIMATRIX CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, May 13)
- CombiMatrix Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
- Q1 2013 Combimatrix Earnings Release - Before Market OpenCCBN(Wed, May 8)
- CombiMatrix Corporation Reports Results for 2013 First QuarterGlobeNewswire(Wed, May 8)
- COMBIMATRIX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Tue, May 7)
- CombiMatrix Executes Equity FinancingGlobeNewswire(Mon, May 6)
- COMBIMATRIX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity SecuritiEDGAR Online(Sun, May 5)
- COMBIMATRIX CORP Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Fri, May 3)
- CombiMatrix Corporation to Release First Quarter Financial Results on May 8, 2013GlobeNewswire(Wed, May 1)
- 5 Health Care Stocks Under $10 Ready to Rip Higherat TheStreet(Thu, Apr 18)
- COMBIMATRIX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity SecuritiEDGAR Online(Mon, Apr 8)
- Stocks to Watch: CombiMatrix, Merrimack, Compuwareat The Wall Street Journal(Thu, Apr 4)
- CombiMatrix reports Q1 growth in prenatal testing volumes of 124%at theflyonthewall.com(Thu, Apr 4)
- CombiMatrix Reports Preliminary Quarterly Growth in Prenatal Testing Volumes of 124% for First QuarterGlobeNewswire(Thu, Apr 4)
- COMBIMATRIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitsEDGAR Online(Wed, Apr 3)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 1.70 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-10)
: | N/A |
|---|
| Quarterly EPS Est
(Dec-10)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
CombiMatrix Corporation, a molecular diagnostics company, operates primarily in the field of genetic analysis and molecular diagnostics. The company, through its subsidiary, CombiMatrix Molecular Diagnostics, Inc., operates a diagnostics reference...
View More